OBGC
ACXP icon

O'Brien Greene & Co’s Acurx Pharmaceuticals ACXP Stock Holding History

O'Brien Greene & Co’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,000
Closed -$30.6K – 129
2025
Q2 		$30.6K Buy
+3,000
New +$24.2K 0.01% 133

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

O'Brien Greene & Co's ACXP Position: Q3 2025 in Review

O'Brien Greene & Co sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 3,000 shares — an estimated $30.6K sold.

O'Brien Greene & Co first reported a position in ACXP in Q2 2025 and held it in 1 quarter. The position peaked at $30.6K in Q2 2025. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • O'Brien Greene & Co reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • O'Brien Greene & Co sold 3,000 Acurx Pharmaceuticals shares in Q3 2025, an estimated $30.6K.
  • O'Brien Greene & Co first reported a position in Acurx Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • O'Brien Greene & Co's Acurx Pharmaceuticals position peaked at $30.6K in Q2 2025.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on O'Brien Greene & Co's 13F filing for Q3 2025, filed 10 Nov 2025.